UK-based CellCentric announced the completion of a $120 million Series C funding round, which will be used to further support the advancement of the company’s novel oral p300/CBP inhibitor, inobrodib, for the treatment of multiple myeloma.
The financing was co-led by RA Capital Management and new investor Forbion, with participation from Avego Bioscience Capital, as well as BrightEdge, the American Cancer Society’s venture capital and impact investment arm.
A phase 2a dose optimization clinical study is ongoing with an all-oral triplet of inobrodib combined with dexamethasone and Bristol Myers Squibb’s Imnovid. Proceeds from the Series C financing will be used to support:
- Initiation of a phase 2/3 study in heavily pretreated multiple myeloma patients, with the potential to support an accelerated approval
- Development activities for a phase 3 program, to start mid-2026
- Initiation of trials starting Q2 2025, including the combination of inobrodib with bi-specific antibodies, as well as inobrodib in a maintenance setting
Delivered as an oral capsule, inobrodib works by binding to a specific part of proteins p300 and CBP (bromodomain). It is highly selective and does not impact similar pockets on other proteins. In 2023, shortly after the FDA granting inobrodib fast track designation for late-stage relapsed refractory multiple myeloma and orphan drug designation in multiple myeloma, Pfizer invested $25 million to help finance further development of the drug.